Rybelsus is the first oral GLP-1 receptor agonist approved for the treatment of type 2 diabetes. Its active ingredient, semaglutide, mimics the natural hormone GLP-1 to help regulate blood sugar levels. Rybelsus works by stimulating insulin secretion in response to meals, inhibiting glucagon release, and slowing gastric emptying, which collectively help lower blood glucose levels. Unlike injectable GLP-1 medications like Ozempic and Wegovy, Rybelsus is taken as a daily oral tablet. It is typically started at a 3 mg dose, which is increased to 7 mg after 30 days, and may be further increased to 14 mg if additional glycemic control is needed. To ensure optimal absorption, Rybelsus should be taken on an empty stomach with no more than 4 ounces of plain water, at least 30 minutes before the first meal or beverage of the day .novomedlink.com+1novomedlink.com+1drugs.com+2drugs.com+2medbroadcast.com+2

Clinical studies have shown that Rybelsus is effective in lowering A1C levels and promoting modest weight loss. In one study, patients taking a 10 mg daily dose experienced an average weight loss of 10.6 pounds over 26 weeks . However, gastrointestinal side effects such as nausea, vomiting, diarrhea, and decreased appetite are common, affecting approximately 30% to 50% of users . Rybelsus is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, due to potential risks observed in animal studies . As with any medication, it is important to use Rybelsus under the guidance of a healthcare provider to ensure safety and efficacy.